Endosialin protein expression and therapeutic target potential in human solid tumors: Sarcoma versus carcinoma

Clinical Cancer Research

Volumn 14, Issue 22, 2008, Pages 7223-7236

  Rouleau, Cecile ^a   Curiel, Maritza ^b   Weber, William ^a   Smale, Robert ^b   Kurtzberg, Leslie ^a   Mascarello, James ^b   Berger, Carol ^b   Wallar, Gina ^b   Bagley, Rebecca ^a   Honma, Nakayuki ^d   Hasegawa, Kazumasa ^d   Ishida, Isao ^d   Kataoka, Shiro ^d   Thurberg, Beth L ^a   Mehraein, Khodadad ^b   Horten, Bruce ^c   Miller, Glenn ^b   Teicher, Beverly A ^a  

^a GENZYME CORPORATION   (United States)

^b GENZYME GENETICS   (United States)

^c Genzyme Genetics   (United States)

^d KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; ENDOSIALIN; IMMUNOGLOBULIN G; SAPORIN; CD248 PROTEIN, HUMAN; IMMUNOTOXIN; LEUKOCYTE ANTIGEN; MESSENGER RNA; RIBOSOME INACTIVATING PROTEIN 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; ENDOTHELIUM CELL; EWING SARCOMA; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; NEUROBLASTOMA; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR CELL LINE; ANIMAL; BIOSYNTHESIS; CARCINOMA; GENETICS; HUMAN; METABOLISM; NEOPLASM; SARCOMA;

ANIMALS; ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOTOXINS; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOME INACTIVATING PROTEINS, TYPE 1; RNA, MESSENGER; SARCOMA;

EID: 58149343911     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0499     Document Type: Article

References (34)

1. Rettig WJ, Garin-Chesa P, Healey JH, Su SL, Jaffe EA, Old LJ. Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci U S A 1992;89:10832-6.
2. Opavsky R, Haviernik P, Jurkovicova D, et al. Molecular characterization of the mouse Tem1/endosialin gene regulated by cell density in vitro and expressed in normal tissues in vivo. J Biol Chem 2001;276:38795-807.
3. Dolznig H, Schweifer N, Puri C, et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun 2005;5:10-9.
4. Rupp C, Dolznig H, Puri C, et al. Mouse endosialin, a C-type lectin-like cell surface receptor: expression during embryonic development and induction in experimental cancer neoangiogenesis. Cancer Immun 2006;6:10-21.
5. MacFadyen JR, Haworth O, Roberston D, et al. Endosialin (TEM1, CD248) is a marker of stromal fibroblasts and is not selectively expressed on tumour endothelium. FEBS Lett 2005;579:2569-75.
6. Lax S, Hou TZ, Jenkinson E, et al. CD248/endosialin is dynamically expressed on a subset of stromal cells during lymphoid tissue development, splenic remodeling and repair. FEBS Lett 2007;581:3550-6.
7. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
8. Christian S, Ahorn H, Koehler A, et al. Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium. J Biol Chem 2001;276:7408-14.
9. Brady J, Neal J, Sadakar N, Gasque P. Human endosialin (tumor endothelial marker 1) is abundantly expressed in highly malignant and invasive brain tumors. J Neuropathol Exp Neurol 2004;63:1274-83.
10. Tentori L, Vergati M, Muzi A, et al. Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. Int J Oncol 2005;27:525-35.
11. Huber MA, Kraut N, Schweifer N, et al. Expression of stromal cell markers in distinct compartments of human skin cancers. J Cutan Pathol 2006;33:145-55.
12. Rupp C, Dolznig H, Puri C, et al. Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. Diagn Mol Pathol 2006;15:35-42.
13. MacFadyen J, Savage K, Wienke D, Isacke CM. Endosialin is expressed on stromal fibroblasts and CNS pericytes in mouse embryos and is downregulated during development. Gene Expr Patterns 2007;7:363-9.
14. Virgintino D, Girolamo F, Errede M, et al. An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis. Angiogenesis 2007;10:35-45.
15. Nanda A, Karim B, Peng Z, et al. Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors. Proc Natl Acad Sci U S A 2006;103:3351-6.
16. Battle TE, Nguyen C, Bagley RG, et al. TEM1/Endosialin participates in cell-matrix and cell-cell adhesion interactions [abstract]. In: American Association for Cancer Research Annual Meeting: Proceedings; 2007 Apr 14-18; Los Angeles, CA. Philadelphia (PA): AACR; 2007. Abstract nr 3026.
17. Tomkowicz B, Rybinski K, Foley B, et al. Interaction of endosialin/TEM1 with extracellular matrix proteins mediates cell adhesion and migration. Proc Natl Acad Sci U S A 2007;104:17965-70.
18. Ishida I, Tomizuka K, Yoshida H, et al. Production of human monoclonal and polyclonal antibodies in transchromo animals. Cloning Stem Cells 2002;4:91-102.
19. Tomizuka K, Shinohara T, Yoshida H, et al. Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and κ loci and expression of fully human antibodies. Proc Natl Acad Sci U S A 2000;97:722-7.
20. Martinez-Ramirez A, Rodriguez-Perales S, Melendez B, et al. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2003;141:138-42.
21. Coleman N, Roberts I. Re: Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet Cytogenet 2004;148:86.
22. Roberts I, Wienberg J, Nacheva E, et al. Novel method for the production of multiple colour chromosome paints for use in karyotyping by fluorescence in situ hybridisation. Genes Chromosomes Cancer 1999;25:241-50.
23. 2-terminal fragment of human fibronectin. Cancer Res 1997;57:3577-84.
24. Teicher BA. Newer vascular targets: endosialin [review]. Int J Oncol 2007;30:305-12.
25. Leyland-Jones B. Maximizing the response to Herceptin therapy through optimal use and patient selection. Anticancer Drugs 2001;12 Suppl 4:S11-7.
26. Willmore C, Holden JA, Layfield LJ. Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay. Appl Immunohistochem Mol Morphol 2005;13:333-41.
27. Tsuda H. HER-2 (c-erbB-2) test update: present status and problems. Breast Cancer 2006;13:236-48.
28. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006;11 Suppl 1:4-12.
29. Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A. Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 2007;62:9-15.
30. Schuetze SM. Chemotherapy in the management of osteosarcoma and Ewing's sarcoma. J Natl Compr Canc Netw 2007;5:449-55.
31. Kasper B, Gil T, Awada A. Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol 2007;19:336-40.
32. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006;18:347-53.
33. Tschoep K, Kohlmann A, Schlemmer M, Haferlach T, Issels RD. Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 2007;63:111-24.
34. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007;109:813-9.